Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Conditioning for Stem Cell Transplant in Multiple Myeloma
NCT00948922Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2009
- Primary completion
- Apr 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM) (3 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Progression Free Survival at 2 years. Started Jun 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00948922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948922.